The company will use its Boettcher Foundation COVID Biomedical Research Innovation Fund grant to build the next generation of pilot-scale ALD system capable of producing 10,000-100,000 doses of vaccines per run, to be ready for use as COVID-19 candidate vaccines begin to emerge.
More Information